Abstract
Our in vitro experiments suggested that tetrahydroxystilbene glucoside (TSG) affords a significant neuroprotective effect against MPP⁺-induced damage and apoptosis in PC12 cells though activation of the PI3K/Akt pathway. This study was aimed to investigate the potential neuroprotective effect of TSG in 1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP)-treated mouse model of Parkinson's disease (PD). We found that treatment of TSG protected dopaminergic neurons by preventing MPTP-induced decreases in substantia nigra tyrosine hydroxylase (TH)-positive cells and striatal dopaminergic transporter (DAT) protein levels. Furthermore, it was also associated with increasing striatal Akt and GSK3β phosphorylation, up-regulation of the Bcl-2/BAD ratio, and inhibition of the activation of caspase-9 and caspase-3. These results showed that TSG promoted dopamine neuron survival in vivo, the PI3K/Akt signaling pathway may have mediated the protection of TSG against MPTP, suggesting that TSG treatment might represent a neuroprotective treatment for PD.
Keywords:
Neuroprotection; Parkinson's disease; Phosphatidylinositol 3-kinase (PI3K)/Akt; Tetrahydroxystilbene glucoside; Tyrosine hydroxylase.
Crown Copyright © 2013. Published by Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Animals
-
Apoptosis Regulatory Proteins / metabolism
-
Ataxia / etiology
-
Ataxia / prevention & control
-
Behavior, Animal / drug effects
-
Cell Survival / drug effects
-
Corpus Striatum / drug effects*
-
Corpus Striatum / metabolism
-
Corpus Striatum / pathology
-
Disease Models, Animal*
-
Dopamine Plasma Membrane Transport Proteins / metabolism
-
Dopaminergic Neurons / drug effects*
-
Dopaminergic Neurons / metabolism
-
Dopaminergic Neurons / pathology
-
Glucosides / therapeutic use*
-
Glycogen Synthase Kinase 3 / metabolism
-
Glycogen Synthase Kinase 3 beta
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Nerve Tissue Proteins / metabolism
-
Neuroprotective Agents / therapeutic use*
-
Parkinson Disease / drug therapy
-
Parkinson Disease / physiopathology
-
Parkinson Disease / prevention & control*
-
Proto-Oncogene Proteins c-akt / metabolism
-
Signal Transduction / drug effects
-
Stilbenes / therapeutic use*
-
Substantia Nigra / drug effects*
-
Substantia Nigra / metabolism
-
Substantia Nigra / pathology
-
Tyrosine 3-Monooxygenase / metabolism
Substances
-
Apoptosis Regulatory Proteins
-
Dopamine Plasma Membrane Transport Proteins
-
Glucosides
-
Nerve Tissue Proteins
-
Neuroprotective Agents
-
Slc6a3 protein, mouse
-
Stilbenes
-
2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Tyrosine 3-Monooxygenase
-
Akt1 protein, mouse
-
Glycogen Synthase Kinase 3 beta
-
Gsk3b protein, mouse
-
Proto-Oncogene Proteins c-akt
-
Glycogen Synthase Kinase 3